Haemonetics Q1 FY 2027 Results: Strong Growth, New Vascular Closure EvidenceHaemonetics releases Q1 FY 2027 results, highlighting strong vascular closure tech gains and a promising VASCADE MVP® XL study.HAEMONETICS CORP/MASS Health Care Health Care Equipment & Services AI generated 06/08/2026, 12:20 2 minutes to read
